Boston Scientific (NYSE:BSX) said yesterday that it inked a deal with Brainlab to enhance their respective deep-brain stimulation technologies by linking them in a distribution deal.
The deal calls for Boston Scientific to distribute Brainlab’s DBS surgical planning software alongside its Vercise DBS system in some international markets. Financial details weren’t disclosed.
Brainlab’s software helps surgeons image, plan and navigate neurological surgeries; Boston Scientific’s Vercise is designed to stimulate targeted areas of the brain to treat movement disorders including Parkinson’s disease, dystonia and essential tumor. Vercise has CE Mark approval in the European Union and is being tested in the U.S. for Parkinson’s.
Maulik Nanavaty, president of Marlborough, Mass-based Boston Scientific’s neuromodulation arm, said the Brainlab deal is a good fit for both companies.
“We have found natural synergies with Brainlab," Nanavaty said in prepared remarks. "This collaboration offers physicians and their patients advanced technology as well as sophisticated software capabilities."
Stephan Holl, Brainlab’s chief operating officer, added in a prepared statement that the collaboration "will streamline and integrate DBS treatments for physicians and their patients."
Brainlab, which is based in Munich, launched in 1989. It’s inked a number of deals with other medical device companies, including Johnson & Johnson’s DePuy-Synthes unit and Jan Medical.
